Valiant Capital Management, L.P. Crispr Therapeutics Ag Transaction History

Valiant Capital Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $1.52 Million - $2.55 Million	38,800 Added 20.4%	228,983 $9.31 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $8.16 Million - $11.2 Million	-133,600 Reduced 41.26%	190,183 $12.4 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $3.59 Million - $6.14 Million	83,100 Added 34.53%	323,783 $19.7 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $3.34 Million - $4.98 Million	62,800 Added 35.3%	240,683 $15.1 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $9.1 Million - $14.4 Million	-129,817 Reduced 42.19%	177,883 $13.5 Million
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $5.26 Million - $9.98 Million	-47,500 Reduced 13.37%	307,700 $37.5 Million
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $9 Million - $19.6 Million	-113,000 Reduced 24.13%	355,200 $54.4 Million
Q1 2020 May 13, 2020	BUY	$33.68 - $62.53 $6.62 Million - $12.3 Million	196,500 Added 72.32%	468,200 $19.9 Million
Q3 2018 Nov 06, 2018	BUY	$44.35 - $65.71 $12 Million - $17.9 Million	271,700 New	271,700 $12.1 Million

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Valiant Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Valiant Capital Management, L.P. with notifications on news.